Information Provided By:
Fly News Breaks for October 13, 2015
HTWR
Oct 13, 2015 | 06:54 EDT
Northland analyst Suraj Kalia lowered his price target for HeartWare to $45 after the company indicated that its MVAD trial might not be starting up in November as originally planned. "There is a crisis of credibility with the Heartware story," alia tells investors in a research note. He keeps a Market Perform rating on the name.
News For HTWR From the Last 2 Days
There are no results for your query HTWR